

Press release, January 30, 2009

New number of shares and votes in Biovitrum AB (publ)

The total number of shares in Biovitrum AB (publ) as per 30 January 2009 amounts to in total 50,098,782 shares, whereof 49,814,782 common shares and 284,000 class C shares, corresponding to in total 49,843,182 votes. The increase in the number of shares and votes results from Biovitrum's asset purchase agreement entered into with Amgen Inc."

For more information please contact:

Biovitrum

Göran Arvidson, CFO
Phone: +46 8 697 23 68

Erik Kinnman, VP Investor Relations
Phone: +46 8 697 21 50
erik.kinnman@biovitrum.com

About Biovitrum

Biovitrum is a Swedish pharmaceutical company. The company markets a range of specialist pharmaceuticals internationally. Using its expertise and experience Biovitrum takes scientific innovation all the way to the market and to specialist indication patients with significant medical need. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within our prioritized areas of hemophilia, inflammation/autoimmune diseases and malabsorption. The company has revenues of approximately SEK 1.3 billion and around 500 employees. It is listed on the OMX Nordic Exchange in Stockholm. For more information go to www.biovitrum.com.

Biovitrum AB (publ) may be required to disclose the information provided herein pursuant to the Swedish Securities Markets Act. The information was provided for public release on January 30, 2009 at 11:30 a.m. CET.